Indications for Daptomycin Use in Endocarditis and Pacemaker Lead Infection and Outcomes in Leeds, UK

• Murdoch DR , CoreyGR, HoenBet al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on endocarditis-prospective cohort study. Arch. Intern. Med. , 169(5), 463–473 (2009).
   PubMedGoogle Scholar
• Fedeli U , SchievanoE, BuonfrateD, PellizzerG, SpolaoreP. Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system. BMC Infect. Dis., 11, 48 (2011).
   PubMed Web of Science ®Google Scholar
• Hill EE , HerijgersP, ClausP, VanderschuerenS, HerregodsMC, PeetermansWE. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur. Heart J., 28(2), 196–203 (2007).
   PubMed Web of Science ®Google Scholar
• Baddour LM , WilsonWR, BayerASet al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation , 111(23), E394–E434 (2005).
   PubMed Web of Science ®Google Scholar
• Warren RE . Daptomycin in endocarditis and bacteraemia: a British perspective. J. Antimicrob. Chemother., 62(Suppl. 3), III25–III33 (2008).
   PubMedGoogle Scholar
• Gould FK , DenningDW, ElliottTSet al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. , 67(2), 269–289 (2012).
   PubMed Web of Science ®Google Scholar
• Hawkey PM . Pre-clinical experience with daptomycin. J. Antimicrob. Chemother., 62(Suppl. 3), III7–III14 (2008).
   PubMedGoogle Scholar
• Boucher HW , SakoulasG. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis., 45(5), 601–608 (2007).
   PubMed Web of Science ®Google Scholar
• Cunha BA , PherezFM. Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE). Eur. J. Clin. Microbiol. Infect. Dis., 28(7), 831–833 (2009).
   PubMed Web of Science ®Google Scholar
• Kirby A , MohandasK, BroughtonCet al. In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis. J. Med. Microbiol., 58(Pt 3), 376–380 (2009).
   PubMed Web of Science ®Google Scholar
• Sakoulas G , RoseW, RybakMJet al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J. Clin. Microbiol. , 46(1), 220–224 (2008).
   PubMed Web of Science ®Google Scholar
• Tenover FC , SinnerSW, SegalREet al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int. J. Antimicrob. Agents , 33(6), 564–568 (2009).
   PubMed Web of Science ®Google Scholar
• van Hal SJ , PatersonDL, GosbellIB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient – a review of the literature. Eur. J. Clin. Microbiol. Infect. Dis., 30(5), 603–610 (2010).
   PubMed Web of Science ®Google Scholar
• Mergenhagen KA , PaskoMT. Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. Ann. Pharmacother., 41(9), 1531–1535 (2007).
   PubMed Web of Science ®Google Scholar
• Kanafani Z , BoucherH, FowlerVet al. Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm. Infecc. Microbiol. Clin. , 28(8), 498–503 (2010).
   PubMed Web of Science ®Google Scholar
• Lappa A , DonfrancescoS, PicozziPet al. Treatment with daptomycin for Corynebacterium jeikeium left-sided prosthetic valve endocarditis. Minerva Anestesiol. , 78(6), 729–732 (2011).
   PubMed Web of Science ®Google Scholar
• Hendolin PH , PaulinL, YlikoskiJ. Clinically applicable multiplex PCR for four middle ear pathogens. J. Clin. Microbiol., 38(1), 125–132 (2000).
   PubMed Web of Science ®Google Scholar
• Murchan S , KaufmannME, DeplanoAet al. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J. Clin. Microbiol. , 41, 1574–1585 (2003).
   PubMed Web of Science ®Google Scholar
• Weisburg WG , BarnsSM, PelletierDA, LaneDJ. 16S ribosomal DNA amplification for phylogenetic study. J. Bacteriol., 173(2), 697–703 (1991).
   PubMed Web of Science ®Google Scholar
• Bosshard PP , AbelsS, AltweggM, BottgerEC, ZbindenR. Comparison of conventional and molecular methods for identification of aerobic catalase-negative Gram-positive cocci in the clinical laboratory. J. Clin. Microbiol., 42(5), 2065–2073 (2004).
   PubMed Web of Science ®Google Scholar
• Fowler VG et al. Jr, Boucher HW, Corey GR Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med., 355(7), 653–665 (2006).
   PubMed Web of Science ®Google Scholar
• Levine DP , LampKC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am. J. Med., 120(10 Suppl. 1), S28–S33 (2007).
   PubMed Web of Science ®Google Scholar
• Segreti JA , CrankCW, FinneyMS. Daptomycin for the treatment of Gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy, 26(3), 347–352 (2006).
   PubMed Web of Science ®Google Scholar
• Levine DP . Clinical experience with daptomycin: bacteraemia and endocarditis. J. Antimicrob. Chemother., 62(Suppl. 3), III35–III39 (2008).
   PubMedGoogle Scholar
• Kullar R , DavisSL, LevineDPet al. High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy , 31(6), 527–536 (2011).
   PubMed Web of Science ®Google Scholar
• Wu G , AbrahamT, RappJ, VasteyF, SaadN, BalmirE. Daptomycin: evaluation of a high-dose treatment strategy. Int. J. Antimicrob. Agents, 38(3), 192–196 (2011).
   PubMed Web of Science ®Google Scholar
• Bassetti M , MikulskaM, SchenoneE, NicoliniL, ViscoliC. Long course of daptomycin in the treatment of meticillin-resistant Staphylococcus epidermidis endocarditis and spondylodiscitis. Int. J. Antimicrob. Agents, 34(3), 290–291 (2009).
   PubMed Web of Science ®Google Scholar
• Lichterfeld M , FerraroMJ, DavisBT. High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. Int. J. Antimicrob. Agents, 35(1), 96 (2010).
   PubMedGoogle Scholar
• Durante-Mangoni E , CasilloR, BernardoMet al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin. Infect. Dis. , 54(3), 347–354 (2012).
   PubMed Web of Science ®Google Scholar
• Hageman JC , PatelJ, FranklinPet al. Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. , 62(4), 440–442 (2008).
   PubMed Web of Science ®Google Scholar
• Huang YT , LiaoCH, TengLJ, HsuehPR. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Clin. Microbiol. Infect., 14(2), 124–129 (2008).
   PubMed Web of Science ®Google Scholar
• Lemaire S , Kosowska-ShickK, JulianK, TulkensPM, Van Bambeke F, Appelbaum PC. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin. Microbiol. Infect., 14(8), 766–777 (2008).
   PubMed Web of Science ®Google Scholar
• Rose WE , LeonardSN, RybakMJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother., 52(9), 3061–3067 (2008).
   PubMed Web of Science ®Google Scholar
• Quader N , MookadamF. Methicillin-resistant Staphylococcus aureus and infective endocarditis: more than a nuisance in the face of resistance. Future Cardiol., 8(4), 499–502 (2012)
   PubMedGoogle Scholar

Websites

• EMA. Daptomycin: summary of product characteristics. www.emea.europa.eu/humandocs/humans/epar/cubicin/cubicin.htm
   Google Scholar
• BLAST®. www.ncbi.nlm.nih.gov/BLAST
   Google Scholar